MXPA03004781A - Moleculas novedosas de acido nucleico humano y polipeptidos que codifican canal de iones de humano novedoso expresado en medula espinal y cerebro. - Google Patents

Moleculas novedosas de acido nucleico humano y polipeptidos que codifican canal de iones de humano novedoso expresado en medula espinal y cerebro.

Info

Publication number
MXPA03004781A
MXPA03004781A MXPA03004781A MXPA03004781A MXPA03004781A MX PA03004781 A MXPA03004781 A MX PA03004781A MX PA03004781 A MXPA03004781 A MX PA03004781A MX PA03004781 A MXPA03004781 A MX PA03004781A MX PA03004781 A MXPA03004781 A MX PA03004781A
Authority
MX
Mexico
Prior art keywords
novel human
disorders
nucleic acid
acid molecules
proteins
Prior art date
Application number
MXPA03004781A
Other languages
English (en)
Inventor
Ramanathan Chandra
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MXPA03004781A publication Critical patent/MXPA03004781A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)

Abstract

La presente invencion se refiere a moleculas de acido nucleico de humano, novedosas que codifican los canales de cationes de humano, novedosos y proteinas y polipeptidos codificados por esas moleculas de acido nucleico. Mas especificamente, las moleculas de acido nucleico de la invencion incluyen genes humanos, novedosos, por ejemplo, hVRld.1 y hVRld.2, que codifican las proteinas o polipeptidos que son expresados en tejidos de la medula espinal y el cerebro y que exhiben homologia de secuencia y homologia estructural con las familias vanilloides y TRP (potenciales receptores, transcientes) de proteinas de canales de cationes. Las proteinas y polipeptidos de la invencion dirigidos a este canal de cationes de humano, novedoso pueden ser objetivos terapeuticamente valiosos para el suministro de farmacos en el tratamiento de enfermedades en humanos que involucran disfunciones en el calcio, sodio, potasio y otra disfuncion de homeostasia de iones, tal como los trastornos en el sistema nervioso central (CNS), por ejemplo, trastornos neurologicos, degenerativos tales como enfermedad de Alzheimer o enfermedad de Parkinson, u otros trastornos tales como dolor cronico, ansiedad y depresion, apoplejia, trastornos cardiacos, por ejemplo, arritmia, diabetes, hipercalcemia, hipocalcemia, hipercalciuria, hipocalciuria o trastornos de iones asociados con trastornos inmunologicos, trastornos del tracto gastrointestinal (GI) o una enfermedad renal o hepatica.
MXPA03004781A 2000-12-01 2001-11-30 Moleculas novedosas de acido nucleico humano y polipeptidos que codifican canal de iones de humano novedoso expresado en medula espinal y cerebro. MXPA03004781A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25058700P 2000-12-01 2000-12-01
PCT/US2001/045336 WO2002044210A2 (en) 2000-12-01 2001-11-30 Novel human nucleic acid molecules and polypeptides encoding a novel human ion channel expressed in spinal cord and brain

Publications (1)

Publication Number Publication Date
MXPA03004781A true MXPA03004781A (es) 2004-04-20

Family

ID=22948356

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03004781A MXPA03004781A (es) 2000-12-01 2001-11-30 Moleculas novedosas de acido nucleico humano y polipeptidos que codifican canal de iones de humano novedoso expresado en medula espinal y cerebro.

Country Status (8)

Country Link
US (1) US20030027164A1 (es)
EP (1) EP1379652A2 (es)
JP (1) JP2005506037A (es)
AU (1) AU2002232456A1 (es)
CA (1) CA2436941A1 (es)
IL (1) IL155613A0 (es)
MX (1) MXPA03004781A (es)
WO (1) WO2002044210A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001270240A1 (en) * 2000-06-26 2002-01-08 Millennium Pharmaceuticals, Inc. Human calcium channels (48000; 52920) and uses thereof
GB0128161D0 (en) * 2001-11-23 2002-01-16 Merck Sharp & Dohme Receptor protein
JP2003310281A (ja) * 2002-01-18 2003-11-05 Takeda Chem Ind Ltd 新規タンパク質およびそのｄｎａ
AU2003226797A1 (en) * 2002-04-16 2003-10-27 Bayer Healthcare Ag Regulation of human transient receptor potential channel
AU2003232513A1 (en) * 2002-04-25 2003-11-10 Rheinische Friedrich-Wilhelms- Universitaet Bonn Pain receptor gene and protein
AU2003283594A1 (en) * 2002-11-18 2004-06-15 Merck Sharp And Dohme Limited Vanilloid receptor-2 ligands for treating anxiety or depression
TWI401254B (zh) * 2005-05-09 2013-07-11 Hydra Biosciences Inc 用於調節ｔｒｐｖ３功能之化合物
US8916550B2 (en) * 2005-05-09 2014-12-23 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
TWI409070B (zh) * 2005-11-04 2013-09-21 Hydra Biosciences Inc 用於調節ｔｒｐｖ３功能之化合物
US7998980B2 (en) 2006-09-15 2011-08-16 Hydra Biosciences, Inc. Compounds for modulating TRPV3 function
WO2008140750A1 (en) * 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
US8392124B2 (en) * 2008-11-14 2013-03-05 The Invention Science Fund I, Llc Food content detector
US8722964B2 (en) 2009-04-23 2014-05-13 Transposagen Biopharmaceuticals, Inc. Genetically engineered or transgenic rats exhibiting a cancer phenotype due to a disruption of germline tumor suppressor genes
US9314005B2 (en) 2009-07-01 2016-04-19 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for severe combined immunodeficiency (SCID)
DK2790687T3 (en) 2011-12-16 2018-11-19 Poseida Therapeutics Inc TRPC4 MODULATORS FOR USE IN TREATMENT OR PREVENTION OF Pain
EP3597223A1 (en) * 2018-07-17 2020-01-22 Centre National De La Recherche Scientifique Peptides for use as cell-penetrating peptides
AU2021212754A1 (en) 2020-01-29 2022-08-04 Kamari Pharma Ltd. Compounds and compositions for use in treating skin disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9537A (en) * 1853-01-11 Arrangement op screw-ctttting dies
US219806A (en) * 1879-09-23 Improvement in measuring devices for creating wantage
GB9713484D0 (en) * 1997-06-27 1997-09-03 Smithkline Beecham Plc Neuroprotective vanilloid compounds
EP1009804B1 (en) * 1997-08-20 2003-10-29 The Regents of the University of California Nucleic acid sequences encoding capsaicin receptor and capsaicin receptor-related polypeptides and uses thereof
WO1999037765A1 (en) * 1998-01-27 1999-07-29 Smithkline Beecham Plc Human vanilloid receptor homologues
EP1320600A1 (en) * 2000-08-03 2003-06-25 Incyte Genomics, Inc. Transporters and ion channels
GB2372993A (en) * 2000-11-03 2002-09-11 Smithkline Beecham Plc Vanilloid Receptor 6

Also Published As

Publication number Publication date
JP2005506037A (ja) 2005-03-03
EP1379652A2 (en) 2004-01-14
IL155613A0 (en) 2003-11-23
US20030027164A1 (en) 2003-02-06
AU2002232456A1 (en) 2002-06-11
WO2002044210A2 (en) 2002-06-06
WO2002044210A3 (en) 2003-11-06
CA2436941A1 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
MXPA03004781A (es) Moleculas novedosas de acido nucleico humano y polipeptidos que codifican canal de iones de humano novedoso expresado en medula espinal y cerebro.
WO2002068471A3 (en) Nucleic acid molecules and polypeptides for a human cation channel polypeptide
RS20050838A (en) Novel peptides that bind to the erythropoietin receptor
EA200501798A1 (ru) Новые пептиды, которые связываются с рецептором к эритропоэтину
WO2001053348A3 (en) Human polypeptides related to the vanilloid and trp families of cation channel proteins and nucleic acids encoding them
EA200800368A1 (ru) Гликозилированный il-7, получение и применение
JPH07506005A (ja) 改変型毛様体神経栄養因子
Fan et al. Isolation and characterization of lactoferrin peptides with stimulatory effect on osteoblast proliferation
DE60220879T2 (de) Polymer-konjugate von neublastin und methoden für deren verwendung
WO2003080856A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
US5457047A (en) DNA Sequences coding for PTH variants, PTH variants, expression vector, bacterial host, use and therapeutic composition
WO2003087338A3 (en) Her-2 receptor tyrosine kinase molecules and uses thereof
WO2003029423A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
MXPA03010728A (es) Moleculas de proteina-2 relacionadas con b7 y uso de las mismas.
WO2004078918A3 (en) Materials and methods relating to therapy and diagnosis using targeting of cells that express dcal-hy polypeptides
WO2003085124A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2023178280A3 (en) Compositions and methods for modulating alpha-synuclein expression
WO2003047611A3 (en) Ptp10d, tec and edtp involved in triglycerid-metabolism
WO2004094598A3 (en) Methods of use for novel human polypeptides encoded by polynucleotides
HUP0203689A2 (hu) Interleukin-1 receptor antagonistaszerű molekulák és ezek használata
WO2002060928A3 (en) Medane genes and proteins
WO2003064589A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2002010400A1 (fr) Nouveau polypeptide, arnt-guanine transglycosylase 17.82, et polynucleotide codant ce polypeptide
WO2003050245A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2004022723A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use